Vaginal Progesterone Has No Diabetogenic Potential in Twin Pregnancies: A Retrospective Case-Control Study on 1686 Pregnancies.
gestational diabetes mellitus
high-risk pregnancy
preterm birth
twin pregnancy
vaginal progesterone
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
15 Jul 2020
15 Jul 2020
Historique:
received:
09
06
2020
revised:
01
07
2020
accepted:
13
07
2020
entrez:
19
7
2020
pubmed:
19
7
2020
medline:
19
7
2020
Statut:
epublish
Résumé
In this study, we aimed to investigate the incidence of gestational diabetes mellitus (GDM) in women who carried twin pregnancies and received vaginal progesterone. In this retrospective cohort study, 203 out of 1686 women with twin pregnancies received natural progesterone (200 mg/day between gestational weeks 16 + 0 and 36 + 0) vaginally for ≥ 4 weeks. The control group consisted of 1483 women with twin pregnancies without progesterone administration. Pearson's Chi squared test, Fisher's exact test, and Student's t-test was used to compare differences between the control and the progesterone-treated groups. A multivariate binary logistic regression was performed to assess relative independent associations on the dependent outcome of GDM incidence. Vaginal progesterone treatment in twin pregnancies had no significant influence on developing GDM ( In twin pregnancies, the use of vaginal progesterone for the prevention of recurrent preterm delivery was not associated with an increased risk of GDM.
Sections du résumé
BACKGROUND
BACKGROUND
In this study, we aimed to investigate the incidence of gestational diabetes mellitus (GDM) in women who carried twin pregnancies and received vaginal progesterone.
METHODS
METHODS
In this retrospective cohort study, 203 out of 1686 women with twin pregnancies received natural progesterone (200 mg/day between gestational weeks 16 + 0 and 36 + 0) vaginally for ≥ 4 weeks. The control group consisted of 1483 women with twin pregnancies without progesterone administration. Pearson's Chi squared test, Fisher's exact test, and Student's t-test was used to compare differences between the control and the progesterone-treated groups. A multivariate binary logistic regression was performed to assess relative independent associations on the dependent outcome of GDM incidence.
RESULTS
RESULTS
Vaginal progesterone treatment in twin pregnancies had no significant influence on developing GDM (
CONCLUSION
CONCLUSIONS
In twin pregnancies, the use of vaginal progesterone for the prevention of recurrent preterm delivery was not associated with an increased risk of GDM.
Identifiants
pubmed: 32679847
pii: jcm9072249
doi: 10.3390/jcm9072249
pmc: PMC7408737
pii:
doi:
Types de publication
Journal Article
Langues
eng
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Biosci Rep. 2001 Oct;21(5):653-66
pubmed: 12168772
J Matern Fetal Neonatal Med. 2019 Oct 3;:1-5
pubmed: 31581869
Exp Clin Endocrinol Diabetes. 2014 Jul;122(7):395-405
pubmed: 25014091
Lancet Glob Health. 2019 Jan;7(1):e37-e46
pubmed: 30389451
Arch Gynecol Obstet. 2018 Dec;298(6):1079-1084
pubmed: 30225687
N Engl J Med. 2003 Jun 12;348(24):2379-85
pubmed: 12802023
Aust N Z J Obstet Gynaecol. 2011 Feb;51(1):26-30
pubmed: 21299505
BMC Pregnancy Childbirth. 2016 Apr 16;16:79
pubmed: 27085320
N Engl J Med. 1999 Aug 26;341(9):660-6
pubmed: 10460818
J Endocrinol. 2014 Apr 22;221(2):273-84
pubmed: 24594616
J Clin Endocrinol Metab. 2013 Nov;98(11):4227-49
pubmed: 24194617
Cochrane Database Syst Rev. 2013 Jul 31;(7):CD004947
pubmed: 23903965
Rev Obstet Gynecol. 2011 Summer;4(2):60-72
pubmed: 22102929
Acta Med Austriaca. 2004;31(5):182-4
pubmed: 15747996
Am J Obstet Gynecol. 2019 Nov;221(5):429-436.e5
pubmed: 31132340
Obstet Gynecol. 2020 Jan;135(1):91-99
pubmed: 31809434
Eur J Obstet Gynecol Reprod Biol. 2018 Nov;230:6-9
pubmed: 30237138
Am J Obstet Gynecol. 2019 Jan;220(1):102.e1-102.e8
pubmed: 30595142
Ultrasound Obstet Gynecol. 2011 Jul;38(1):10-7
pubmed: 21465606
Clin Obstet Gynecol. 1998 Mar;41(1):3-11
pubmed: 9504218
Obstet Gynecol. 2019 Mar;133(3):468-475
pubmed: 30741815
J Obstet Gynaecol Can. 2013 Sep;35(9):793-801
pubmed: 24099444
J Matern Fetal Neonatal Med. 2019 Feb;32(3):369-376
pubmed: 28889776
Int J Mol Sci. 2018 Oct 26;19(11):
pubmed: 30373146
Clin Endocrinol (Oxf). 2000 Nov;53(5):615-20
pubmed: 11106923
Ultrasound Obstet Gynecol. 2017 Mar;49(3):303-314
pubmed: 28067007
Obstet Gynecol Sci. 2017 Sep;60(5):405-420
pubmed: 28989916
BJOG. 2014 Mar;121(4):457-62
pubmed: 24148580
Front Physiol. 2018 Aug 17;9:1091
pubmed: 30174608
Diabetes Care. 2012 Mar;35(3):526-8
pubmed: 22355019
Am J Obstet Gynecol. 2009 Oct;201(4):392.e1-5
pubmed: 19716543
Diabet Med. 2012 Jul;29(7):844-54
pubmed: 22150506
Twin Res Hum Genet. 2008 Oct;11(5):552-7
pubmed: 18828739
Am J Obstet Gynecol. 2010 Jun;202(6):654.e1-6
pubmed: 20510967
J Matern Fetal Neonatal Med. 2019 Feb;32(4):687-694
pubmed: 28969466
Twin Res Hum Genet. 2019 Feb;22(1):62-69
pubmed: 30661509
Am J Obstet Gynecol. 1999 Oct;181(4):912-4
pubmed: 10521752
Reprod Sci. 2010 Jun;17(6):532-9
pubmed: 20360593
J Matern Fetal Neonatal Med. 2010 Dec;23(12):1365-76
pubmed: 21067303
Adv Biomed Res. 2015 Oct 29;4:242
pubmed: 26682208
J Obes. 2014;2014:563243
pubmed: 25405027
J Perinat Med. 2016 Oct 1;44(8):893-897
pubmed: 27639267
Obstet Gynecol. 2009 Jul;114(1):45-9
pubmed: 19546757